良性前列腺增生的超微创术式研究进展
Research Progress of Ultra-Minimally Invasive Surgery for Benign Prostatic Hyperplasia
DOI: 10.12677/acm.2026.161085, PDF,   
作者: 杨 越：成都中医药大学医学与生命科学学院，四川 成都；奉友刚：遂宁市中心医院泌尿外科，四川 遂宁
关键词: 前列腺增生；超微创术式；Benign Prostatic Hyperplasia； Ultra-Minimally Invasive Surgical Methods
摘要: 良性前列腺增生是我国中老年男性群体中高发的泌尿系统疾病，以排尿功能障碍为核心临床表现。该疾病的发病率呈明显年龄相关性递增趋势，并且近些年发现其发病年龄逐渐年轻化。想要快速缓解症状应首选外科治疗。前列腺增生外科治疗方案很多，目前外科治疗的金标准为经尿道前列腺电切术，该术式虽能有效缓解排尿困难等下尿路症状，但其临床应用中仍伴随多种不可忽视的并发症包括术中出血较多、电切综合征、尿道狭窄、勃起功能障碍等，这些问题严重影响了患者术后的就医满意度和生活质量。随着医疗技术的不断发展和以患者为中心的外科治疗理念指导下，前列腺增生的超微创术式逐渐受到重视。本文就前列腺增生的超微创术式研究进展进行综述。
Abstract: Benign prostatic hyperplasia (BPH) is a highly prevalent urinary system disease among middle-aged and elderly men in China, with urination dysfunction as the core clinical manifestation. The incidence of this disease shows a significant age-related increasing trend, and in recent years, it has been found that the age of onset is gradually getting younger. To relieve symptoms quickly, surgical treatment should be the first choice. There are many surgical treatment options for benign prostatic hyperplasia. Currently, the gold standard for surgical treatment is transurethral resection of the prostate (TURP). Although this surgical method can effectively relieve lower urinary tract symptoms such as difficulty in urination, it still accompanies many complications that cannot be ignored in clinical application, including excessive intraoperative bleeding, transurethral resection syndrome, urethral stricture, erectile dysfunction, etc. These problems have seriously affected patients' satisfaction with medical treatment and quality of life after surgery. With the continuous development of medical technology and under the guidance of the patient-centered surgical treatment concept, the ultra-minimally invasive surgical methods for benign prostatic hyperplasia have gradually received attention. This article reviews the research progress of ultra-minimally invasive surgical methods for benign prostatic hyperplasia.
文章引用：杨越, 奉友刚. 良性前列腺增生的超微创术式研究进展[J]. 临床医学进展, 2026, 16(1): 634-642. https://doi.org/10.12677/acm.2026.161085

参考文献

[1] Lerner, L.B., McVary, K.T., Barry, M.J., Bixler, B.R., Dahm, P., Das, A.K., et al. (2021) Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I—Initial Work-Up and Medical Management. Journal of Urology, 206, 806-817. [Google Scholar] [CrossRef] [PubMed]
[2] Xu, X., Liu, G., Guo, Y., Zhu, H., He, D., Qiao, X., et al. (2021) Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019. American Journal of Men’s Health, 15, 1-13. [Google Scholar] [CrossRef] [PubMed]
[3] Murad, L., Bouhadana, D., Nguyen, D., Chughtai, B., Zorn, K.C., Bhojani, N., et al. (2023) Treating LUTS in Men with Benign Prostatic Obstruction: A Review Article. Drugs & Aging, 40, 815-836. [Google Scholar] [CrossRef] [PubMed]
[4] Abreu-Mendes, P., Silva, J. and Cruz, F. (2020) Pharmacology of the Lower Urinary Tract: Update on LUTS Treatment. Therapeutic Advances in Urology, 12, 1-16. [Google Scholar] [CrossRef] [PubMed]
[5] Gul, Z.G. and Kaplan, S.A. (2019) BPH: Why Do Patients Fail Medical Therapy? Current Urology Reports, 20, Article No. 40. [Google Scholar] [CrossRef] [PubMed]
[6] Miernik, A. and Gratzke, C. (2020) Current Treatment for Benign Prostatic Hyperplasia. Deutsches Ärzteblatt international, 117, Article No. 843. [Google Scholar] [CrossRef] [PubMed]
[7] Kim, E.H., Larson, J.A. and Andriole, G.L. (2016) Management of Benign Prostatic Hyperplasia. Annual Review of Medicine, 67, 137-151. [Google Scholar] [CrossRef] [PubMed]
[8] Nørby, B., Røder, A., Graugaard-Jensen, C., et al. (2023) Treatment of Benign Prostatic Hyperplasia. Ugeskrift for Laeger, 185, V10220650.
[9] Russo, G.I., Kurbatov, D., Sansalone, S., Lepetukhin, A., Dubsky, S., Sitkin, I., et al. (2015) Prostatic Arterial Embolization vs Open Prostatectomy: A 1-Year Matched-Pair Analysis of Functional Outcomes and Morbidities. Urology, 86, 343-348. [Google Scholar] [CrossRef] [PubMed]
[10] Rukstalis, D., Grier, D., Stroup, S.P., Tutrone, R., deSouza, E., Freedman, S., et al. (2018) Prostatic Urethral Lift (PUL) for Obstructive Median Lobes: 12 Month Results of the Medlift Study. Prostate Cancer and Prostatic Diseases, 22, 411-419. [Google Scholar] [CrossRef] [PubMed]
[11] Page, T., Veeratterapillay, R., Keltie, K., Burn, J. and Sims, A. (2021) Prostatic Urethral Lift (Urolift): A Real-World Analysis of Outcomes Using Hospital Episodes Statistics. BMC Urology, 21, Article No. 11. [Google Scholar] [CrossRef] [PubMed]
[12] Xia, Y., Yuan, T., Zou, W., Li, H., Ning, J., Ruan, Y., et al. (2023) Biocompatibility and Efficacy of Prostatic Urethral Lift in Benign Prostate Hyperplasia: An in Vivo and in Vitro Study. Scientific Reports, 13, Article No. 13828. [Google Scholar] [CrossRef] [PubMed]
[13] Das, A.K., Han, T.M. and Hardacker, T.J. (2020) Holmium Laser Enucleation of the Prostate (HoLEP): Size-Independent Gold Standard for Surgical Management of Benign Prostatic Hyperplasia. Canadian Journal of Urology, 27, 44-50.
[14] Userovici, M., Ochoa, A., Anract, J., Beurrier, S., Peyromaure, M. and Barry Delongchamps, N. (2020) Pose d’implants Urolift® intra-prostatique pour hyperplasie bénigne de la prostate: Résultats après 7 ans d’expérience. Progrès en Urologie, 30, 147-154. [Google Scholar] [CrossRef] [PubMed]
[15] Shah, B.B., Tayon, K., Madiraju, S., Carrion, R.E. and Perito, P. (2018) Prostatic Urethral Lift: Does Size Matter? Journal of Endourology, 32, 635-638. [Google Scholar] [CrossRef] [PubMed]
[16] Kaplan, S.A. (2018) Re: Five Year Results of the Prospective Randomized Controlled Prostatic Urethral L.I.F.T. Study. Journal of Urology, 200, 920-921. [Google Scholar] [CrossRef] [PubMed]
[17] Tutrone, R.F. and Schiff, W. (2021) Re: Early Patient Experience following Treatment with the UroLift Prostatic Urethral Lift and Rezum Steam Injection. Journal of Urology, 206, 1491-1491.
[18] Villard, N., Tsoumakidou, G., Moldovan, P.C., Rosset, R., Rouvière, O., Fassi-Fehri, H., et al. (2024) Giant Prostatic Hyperplasia in a 54-Years Old Patient Treated by Prostate Artery Embolization: Case Report. Frontiers in Urology, 4, Article ID: 1446650. [Google Scholar] [CrossRef] [PubMed]
[19] Insausti, I., Galbete, A., Lucas-Cava, V., de Ocáriz, A.S., Solchaga, S., Monreal, R., et al. (2022) Prostatic Artery Embolization (PAE) Using Polyethylene Glycol Microspheres: Safety and Efficacy in 81 Patients. CardioVascular and Interventional Radiology, 45, 1339-1348. [Google Scholar] [CrossRef] [PubMed]
[20] Hughes, T., Harper, P. and Somani, B.K. (2023) Treatment Algorithm for Management of Benign Prostatic Obstruction: An Overview of Current Techniques. Life, 13, Article 2077. [Google Scholar] [CrossRef] [PubMed]
[21] Pisco, J.M., Bilhim, T., Costa, N.V., Torres, D., Pisco, J., Pinheiro, L.C., et al. (2020) Randomised Clinical Trial of Prostatic Artery Embolisation versus a Sham Procedure for Benign Prostatic Hyperplasia. European Urology, 77, 354-362. [Google Scholar] [CrossRef] [PubMed]
[22] Zumstein, V., Betschart, P., Vetterlein, M.W., Kluth, L.A., Hechelhammer, L., Mordasini, L., et al. (2019) Prostatic Artery Embolization versus Standard Surgical Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. European Urology Focus, 5, 1091-1100. [Google Scholar] [CrossRef] [PubMed]
[23] Xu, X.J., Li, J., Huang, X.Z. and Liu, Q. (2020) An Updated Meta-Analysis of Prostatic Arterial Embolization versus Transurethral Resection of the Prostate in the Treatment of Benign Prostatic Hyperplasia. World Journal of Urology, 38, 2455-2468. [Google Scholar] [CrossRef] [PubMed]
[24] Knight, G.M., Talwar, A., Salem, R. and Mouli, S. (2021) Systematic Review and Meta-Analysis Comparing Prostatic Artery Embolization to Gold-Standard Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. CardioVascular and Interventional Radiology, 44, 183-193. [Google Scholar] [CrossRef] [PubMed]
[25] Abt, D., Müllhaupt, G., Hechelhammer, L., Markart, S., Güsewell, S., Schmid, H., et al. (2021) Prostatic Artery Embolisation versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-Yr Outcomes of a Randomised, Open-Label, Single-Centre Trial. European Urology, 80, 34-42. [Google Scholar] [CrossRef] [PubMed]
[26] Veyg, D., Mohanka, R., Rumball, I.P., Liang, R., Garcia-Reyes, K., Bishay, V., et al. (2023) Comparison of 24-Month Clinical Outcomes after Prostatic Artery Embolization in Prostate Glands Larger versus Smaller than 80 ML: A Systematic Review. Journal of Vascular and Interventional Radiology, 34, 578-584.e1. [Google Scholar] [CrossRef] [PubMed]
[27] Richardson, A.J., Acharya, V., Kably, I. and Bhatia, S. (2020) Prostatic Artery Embolization: Variant Origins and Collaterals. Techniques in Vascular and Interventional Radiology, 23, Article 100690. [Google Scholar] [CrossRef] [PubMed]
[28] Franco, J.V., Jung, J.H., Imamura, M., Borofsky, M., Omar, M.I., Escobar Liquitay, C.M., et al. (2021) Minimally Invasive Treatments for Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia: A Network Meta-Analysis. Cochrane Database of Systematic Reviews, No. 7, CD013656. [Google Scholar] [CrossRef] [PubMed]
[29] Kristensen-Alvarez, A., Fode, M., Stroomberg, H.V., Nielsen, K.K., Arch, A., Lönn, L.B., et al. (2024) Non-Inferiority, Randomised, Open-Label Clinical Trial on the Effectiveness of Transurethral Microwave Thermotherapy Compared to Prostatic Artery Embolisation in Reducing Severe Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia: Study Protocol for the TUMT-PAE-1 Trial. Trials, 25, Article No. 574. [Google Scholar] [CrossRef] [PubMed]
[30] Franco, J.V.A., Garegnani, L., Escobar Liquitay, C.M., Borofsky, M. and Dahm, P. (2022) Transurethral Microwave Thermotherapy for Benign Prostatic Hyperplasia: An Updated Cochrane Review. The World Journal of Men’s Health, 40, Article 127. [Google Scholar] [CrossRef] [PubMed]
[31] Ziętek, R.J. and Ziętek, Z.M. (2021) Transurethral Microwave Thermotherapy (TUMT) in the Treatment of Benign Prostatic Hyperplasia: A Preliminary Report. Medical Science Monitor, 27, e931597-1. [Google Scholar] [CrossRef] [PubMed]
[32] Franco, J.V., Garegnani, L., Escobar Liquitay, C.M., Borofsky, M. and Dahm, P. (2021) Transurethral Microwave Thermotherapy for the Treatment of Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia. Cochrane Database of Systematic Reviews, No. 6, CD004135. [Google Scholar] [CrossRef] [PubMed]
[33] Law, Y.X.T., Chen, W.J.K., Shen, L. and Chua, W.J. (2019) Is Transurethral Needle Ablation of Prostate Out of Fashion? Outcomes of Single Session Office-Based Transurethral Needle Ablation of Prostate in Patients with Symptomatic Benign Prostatic Hyperplasia. Investigative and Clinical Urology, 60, 351-358. [Google Scholar] [CrossRef] [PubMed]
[34] Hill, B., Belville, W., Bruskewitz, R., Issa, M., Perez-Marrero, R., Roehrborn, C., et al. (2004) Transurethral Needle Ablation versus Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia: 5-Year Results of a Prospective, Randomized, Multicenter Clinical Trial. Journal of Urology, 171, 2336-2340. [Google Scholar] [CrossRef] [PubMed]
[35] Dixon, C., Cedano, E.R., Mynderse, L. and Larson, T. (2015) Transurethral Convective Water Vapor as a Treatment for Lower Urinary Tract Symptomatology Due to Benign Prostatic Hyperplasia Using the Rezūm® System: Evaluation of Acute Ablative Capabilities in the Human Prostate. Research and Reports in Urology, 7, 13-18. [Google Scholar] [CrossRef] [PubMed]
[36] McVary, K.T., Gange, S.N., Gittelman, M.C., Goldberg, K.A., Patel, K., Shore, N.D., et al. (2016) Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Journal of Urology, 195, 1529-1538. [Google Scholar] [CrossRef] [PubMed]
[37] Cantrill, C.H., Zorn, K.C., Elterman, D.S., et al. (2019) The Rezūm System—A Minimally Invasive Water Vapor Thermal Therapy for Obstructive Benign Prostatic Hyperplasia. Canadian Journal of Urology, 26, 9787-9793.
[38] McVary, K.T., Rogers, T. and Roehrborn, C.G. (2019) Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 4-Year Results from Randomized Controlled Study. Urology, 126, 171-179. [Google Scholar] [CrossRef] [PubMed]
[39] Bole, R., Gopalakrishna, A., Kuang, R., Alamiri, J., Yang, D.Y., Helo, S., et al. (2020) Comparative Postoperative Outcomes of Rezūm Prostate Ablation in Patients with Large versus Small Glands. Journal of Endourology, 34, 778-781. [Google Scholar] [CrossRef] [PubMed]
[40] Leong, J.Y., Tokarski, A.T., Roehrborn, C.G., et al. (2021) UroLift and Rezum: Minimally Invasive Surgical Therapies for the Management of Benign Prostatic Hyperplasia. Canadian Journal of Urology, 28, 2-5.
[41] Roehrborn, C.G., Teplitsky, S. and Das, A.K. (2019) Aquablation of the Prostate: A Review and Update. Canadian Journal of Urology, 26, 20-24.
[42] Taktak, S., Jones, P., Haq, A., Rai, B.P. and Somani, B.K. (2018) Aquablation: A Novel and Minimally Invasive Surgery for Benign Prostate Enlargement. Therapeutic Advances in Urology, 10, 183-188. [Google Scholar] [CrossRef] [PubMed]
[43] Faber, K., de Abreu, A.L.C., Ramos, P., Aljuri, N., Mantri, S., Gill, I., et al. (2015) Image-Guided Robot-Assisted Prostate Ablation Using Water Jet-Hydrodissection: Initial Study of a Novel Technology for Benign Prostatic Hyperplasia. Journal of Endourology, 29, 63-69. [Google Scholar] [CrossRef] [PubMed]
[44] Gilling, P., Barber, N., Bidair, M., Anderson, P., Sutton, M., Aho, T., et al. (2018) WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation ® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. Journal of Urology, 199, 1252-1261. [Google Scholar] [CrossRef] [PubMed]
[45] Barber, N., Gilling, P., Bidair, M., Anderson, P., Sutton, M.A., Aho, T., et al. (2020) Two-Year Outcomes after Aquablation Compared to TURP: Results from a Blinded Randomized Trial. European Urology Open Science, 19, e376. [Google Scholar] [CrossRef] 
[46] Zorn, K.C., Bidair, M., Trainer, A., Arther, A., Kramolowsky, E., Desai, M., et al. (2021) Aquablation Therapy in Large Prostates (80-150 Cc) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: WATER II 3‐Year Trial Results. BJUI Compass, 3, 130-138. [Google Scholar] [CrossRef] [PubMed]
[47] Cheema, A.S., Long, B.G., Moore, K.E. and McVary, K.T. (2025) Urolift, Rezūm, and Itind for Benign Prostatic Hyperplasia. Urologic Clinics of North America, 52, 547-558. [Google Scholar] [CrossRef] 
[48] Fiori, C., Cillis, S.D., Volpi, G., Checcucci, E., Cattaneo, G., Meziere, J., et al. (2021) Itind for BPH: Technique and Procedural Outcomes: A Narrative Review of Current Literature. Türk Üroloji Dergisi/Turkish Journal of Urology, 47, 470-481. [Google Scholar] [CrossRef] [PubMed]
[49] Balakrishnan, D., Jones, P. and Somani, B.K. (2020) iTIND: The Second-Generation Temporary Implantable Nitinol Device for Minimally Invasive Treatment of Benign Prostatic Hyperplasia. Therapeutic Advances in Urology, 12, 1-5. [Google Scholar] [CrossRef] [PubMed]
[50] Chughtai, B., Elterman, D., Shore, N., Gittleman, M., Motola, J., Pike, S., et al. (2021) The Itind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Urology, 153, 270-276. [Google Scholar] [CrossRef] [PubMed]
[51] Amparore, D., Fiori, C., Valerio, M., Schulman, C., Giannakis, I., De Cillis, S., et al. (2020) 3-Year Results Following Treatment with the Second Generation of the Temporary Implantable Nitinol Device in Men with LUTS Secondary to Benign Prostatic Obstruction. Prostate Cancer and Prostatic Diseases, 24, 349-357. [Google Scholar] [CrossRef] [PubMed]
[52] Kaplan, S.A., Pichardo, M., Rijo, E., Espino, G., Lay, R.R. and Estrella, R. (2021) One-Year Outcomes after Treatment with a Drug-Coated Balloon Catheter System for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia. Prostate Cancer and Prostatic Diseases, 24, 1073-1079. [Google Scholar] [CrossRef] [PubMed]
[53] Gauhar, V., Yuen, S.K.K., Gadzhiev, N., Wroclawski, M., Pirola, G.M., Lim, E.J., et al. (2025) Optilume, a Minimally Invasive Solution for BPH and Urethral Stricture: What We Know, What We Need? An EAU Endourology Scoping Review. BMC Urology, 25, Article No. 196. [Google Scholar] [CrossRef] [PubMed]
[54] Saffarzadeh, M., Derigs, M., Ren, R., Bhojani, N., Elterman, D. and Forbes, C.M. (2025) Device Profile of Optilume BPH Catheter System for Minimally Invasive Treatment of Benign Prostatic Hyperplasia. Expert Review of Medical Devices, 22, 1081-1091. [Google Scholar] [CrossRef] [PubMed]
[55] Kaplan, S.A., Moss, J., Freedman, S., Coutinho, K., Wu, N., Efros, M., et al. (2023) The PINNACLE Study: A Double-Blind, Randomized, Sham-Controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Journal of Urology, 210, 500-509. [Google Scholar] [CrossRef] [PubMed]

为你推荐